SEC Info℠

Home

Search

My Interests

Help

Sign In

Please Sign In

Bone Biologics Corp. – ‘S-8’ on 9/15/23

On:  Friday, 9/15/23, at 4:48pm ET   ·   Effective:  9/15/23   ·   Accession #:  1493152-23-32780   ·   File #:  333-274545

Previous ‘S-8’:  ‘S-8’ on 8/4/16   ·   Latest ‘S-8’:  This Filing   ·   13 References:   To:  Bone Biologics Corp. – ‘8-K’ on / for 9/12/23 To:  Bone Biologics Corp. – ‘10-Q’ on 8/14/23 for 6/30/23 To:  Bone Biologics Corp. – ‘DEF 14A’ on / for 8/3/23 To:  Bone Biologics Corp. – ‘8-K’ on 7/5/23 for 6/28/23 To:  Bone Biologics Corp. – ‘8-K’ on 6/16/23 for 6/14/23 To:  Bone Biologics Corp. – ‘8-K’ on 6/6/23 for 6/5/23 To:  Bone Biologics Corp. – ‘8-K’ on 5/19/23 for 5/18/23 To:  Bone Biologics Corp. – ‘10-Q’ on 5/15/23 for 3/31/23 To:  Bone Biologics Corp. – ‘10-K’ on 3/30/23 for 12/31/22 To:  Bone Biologics Corp. – ‘8-K’ on 3/8/22 for 3/3/22 To:  Bone Biologics Corp. – ‘8-A12B’ on 10/8/21 To:  Bone Biologics Corp. – ‘8-K’ on 1/4/16 for 12/28/15 To:  Bone Biologics Corp. – ‘8-K’ on 9/25/14 for 9/19/14 

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

 Text Wildcards:  ? (any letter/digit),  * (many).  Search Logic:  for Documents:  & (and),  | (or);  for Text:  | (anywhere),  "(&)" (near).  Details... 

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/15/23  Bone Biologics Corp.              S-8         9/15/23    4:121K                                   M2 Compliance LLC/FA

Document/Exhibit                   Description                      Pages   Size 

 1: S-8         Registration Statement - Securities for an          HTML     68K 
                Employee Benefit Plan                                            
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     15K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML      5K 
 4: EX-FILING FEES  Filing Fees                                     HTML     13K 

As filed with the Securities and Exchange Commission on September 15, 2023

Registration No. 333-_______

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM S-8

REGISTRATION STATEMENT UNDER THE

SECURITIES ACT OF 1933

BONE BIOLOGICS CORPORATION

(Exact name of registrant as specified in its charter)

2 Burlington Woods Drive, Suite 100

Burlington, MA 01803

(Address of principal executive offices) (Zip code)

Bone Biologics Corporation 2015 Equity Incentive Plan

(Full title of the plan)

Jeffrey Frelick

Chief Executive Officer

Bone Biologics Corporation

2 Burlington Woods Drive, Suite 100

Burlington, MA 01803

(Name and address of agent for service)

(781) 552-4452

(Telephone number, including area code, of agent for service)

Copy to:

Alexander R. McClean

Harter Secrest & Emery LLP

1600 Bausch & Lomb Place

Rochester, NY 14604

(585) 231-1248

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE

On August 3, 2016, Bone Biologics Corporation, or the Company, filed a Registration Statement on Form S-8 (File No. 333-212890), or the Original Registration Statement, with the Securities and Exchange Commission, to register an aggregate of 35,918 shares of common stock of the Company, par value $0.001 per share, or Common Stock, that may be issued pursuant to the Company’s 2015 Equity Incentive Plan, or the 2015 Plan.

The Company is filing this Registration Statement to register an additional 5,000,000 shares of Common Stock that may be issued under the 2015 Plan. The Company’s stockholders approved increasing the shares of Common Stock under the 2015 Plan by 5,000,000 shares at the Company’s Annual Meeting of Stockholders on September 12, 2023.

All of the share amounts presented herein reflect the 30-to-1 reverse stock split effective June 5, 2023, the 2.5-to-1 reverse stock split effective October 8, 2021, and the 10-to-1 reverse stock split effective July 16, 2018.

The Original Registration Statements is currently effective. Pursuant to General Instruction E to Form S-8, the contents of the Original Registration Statement, including all attachments and exhibits thereto, are incorporated herein by reference, except as amended hereby.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference

The following documents previously filed by Bone Biologics Corporation ( the “Company,” or “our,”) with the Securities and Exchange Commission under the Securities Exchange Act of 1934 (the “Exchange Act”) are incorporated by reference in this registration statement (except for portions thereof furnished or otherwise not filed with the SEC pursuant to Items 2.02 or 7.01 of Form 8-K and corresponding information furnished under Item 9.01 of Form 8-K, which are deemed not to be incorporated by reference into this Registration Statement):

In addition to the foregoing, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the effective date of this Registration Statement (except for the portions thereof furnished or otherwise not filed with the SEC which are deemed not to be incorporated by reference into this Registration Statement), but prior to the filing of a post-effective amendment which indicates that all securities offered hereunder have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents and reports.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 8. Exhibits

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Burlington, in the Commonwealth of Massachusetts, on September 15, 2023.

POWER OF ATTORNEY

We, the undersigned officers and directors of Bone Biologics Corporation, hereby constitute and appoint Jeffrey Frelick, his or her true and lawful attorney-in-fact and agent with full powers of substitution and resubstituting, to sign for him or her and in his or her name in the capacities indicated below any and all amendments or supplements to this registration statement on Form S-8 (including post-effective amendments and registration statements filed pursuant to Rule 462 under the Securities Act of 1933, as amended, and otherwise) and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof. Each of the undersigned has executed this power of attorney as of the date indicated.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘S-8’ Filing		Date		Other Filings
Filed on / Effective on:		9/15/23
		9/12/23		4,  8-K
		8/14/23		10-Q
		6/5/23		8-K
		5/15/23		10-Q
		3/30/23		10-K
		12/31/22		10-K,  ARS
		10/8/21		8-A12B,  CORRESP
		7/16/18		3,  8-K
		8/3/16
				List all Filings

---

13 Previous Filings that this Filing References

As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/12/23 Bone Biologics Corp. 8-K:5 9/12/23 11:265K M2 Compliance LLC/FA 8/14/23 Bone Biologics Corp. 10-Q 6/30/23 51:3.6M M2 Compliance LLC/FA 8/03/23 Bone Biologics Corp. DEF 14A 8/03/23 1:1.6M M2 Compliance LLC/FA 7/05/23 Bone Biologics Corp. 8-K:8 6/28/23 11:241K M2 Compliance LLC/FA 6/16/23 Bone Biologics Corp. 8-K:1,8,9 6/14/23 13:615K M2 Compliance LLC/FA 6/06/23 Bone Biologics Corp. 8-K:5,9 6/05/23 12:3.1M M2 Compliance LLC/FA 5/19/23 Bone Biologics Corp. 8-K:3 5/18/23 11:246K M2 Compliance LLC/FA 5/15/23 Bone Biologics Corp. 10-Q 3/31/23 51:3.3M M2 Compliance LLC/FA 3/30/23 Bone Biologics Corp. 10-K 12/31/22 58:5.5M M2 Compliance LLC/FA 3/08/22 Bone Biologics Corp. 8-K:1,5,8,9 3/03/22 13:574K M2 Compliance LLC/FA 10/08/21 Bone Biologics Corp. 8-A12B 1:28K M2 Compliance LLC/FA 1/04/16 Bone Biologics Corp. 8-K:1,5,9 12/28/15 6:444K M2 Compliance LLC/FA 9/25/14 Bone Biologics Corp. 8-K:1,2,3,5 9/19/14 79:9M M2 Compliance LLC/FA

↑Top

---

Filing Submission 0001493152-23-032780   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

---

---

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 14, 3:33:19.2pm ET